HempNewsBreaks – Marijuana Company of America, Inc. (MCOA) Announces Changes in Corporate Leadership, Vertical Expansion Strategy

Marijuana Company of America (OTCQB: MCOA), an innovative hemp and cannabis corporation, today announced the resignation of Donald J. Steinberg as chairman of the board, chief executive officer and treasurer. According to the update, the Company’s new focus will be to enter strategic acquisitions with various operational cannabis and hemp companies that are distressed in order to expand its vertical model, as well as expand its hempSMART(TM) branded product lines and marketing channels and launch other CBD brands using a direct-to-consumer sales approach. “It has been an honor to lead the Company these past four years and to serve the customers, stakeholders, and staff who have been part of the foundation of the Company,” Steinberg, one of MCOA’s founders, said in the news release. “I am proud of what we have accomplished as a team thus far and know that the Company will continue to grow its presence in the cannabis industry. Also, I am positive that the Company will create additional innovative ideas and pioneering technologies for its customers and stakeholders worldwide and make the right corporate maneuvers and strategic acquisitions to establish meaningful scale in the industry. As many of you know, one of my passions is the development of start-up ventures. I believe in the future of the cannabis marketplace and greatly desire to be a part of advancing the innumerable opportunities that are yet to be discovered. For this reason, I have decided to step down as CEO to allow the Company to pursue new groundbreaking opportunities under new leadership.”

To view the full press release, visit http://cnw.fm/Z6Xp3

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART(TM)” that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) the expansion of its business into ancillary areas as market opportunities in this segment mature and develop. For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com.

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://cnw.fm/MCOA

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

HempWireNews is part of the InvestorBrandNetwork.

420 with CNW – Cannabis Legalization Opponents Admit Federal Policy is Blocking Research

Apart from marijuana legalization advocates, Friends of the National Institute on Drug Abuse (FNIDA) have also recognized that the federal authorities’ restrictions on marijuana are inhibiting cannabis research. FNIDA also raised the issue of federal limitations to Congress.

FNIDA submitted a proposal to a Senate committee on federal restrictions indicating that the status of marijuana and other drugs on the controlled substances list is inhibiting researchers from conducting studies on the drugs.

The group (FNIDA) also requested a federal agency, NIDA, to release a report containing all the research hurdles associated with the controlled substance status of cannabis.

In a new document published by the Senate, FNIDA describes itself as a coalition of more than 150 scientific and research communities, patient groups, and other organizations whose commitment is to prevent and treat drug use disorders.

The group aims to have the Department of Labor, Health and Human Services, as well as the Department of Education and related agencies adopting their language in the financial report for the year 2019. The recommendations made by FNIDA were published earlier this month by the Government Publishing Office, although it is not certain when they submitted their statement.

FNIDA is concerned that the federal restrictions are hindering research on drugs classified as Schedule 1, such as cannabis or its compounds. Currently, we need every information regarding the drugs, and instead of heaping on the restrictions, the agency should be lowering them and other hurdles inhibiting scientists from conducting research. The Appropriations Committee directed NIDA to write a report on the barriers to research on drugs and components that are classified as controlled substances.

Some members of FNIDA, such as Kevin Sabet, publicly challenged the letter submitted to the Senate. Sabet argued that rescheduling of the drug is not a must to supporting research efforts. Kevin Sabet is the president of Smart Approaches to Marijuana; he also serves on the group’s Board of Scientific Advisors.

In 2015, Sabet’s group said that drug rescheduling would not solve the challenge for the need for more research on the drug; instead, it would encourage the illicit operators to continue manufacturing poor quality products.

Sabet wrote in the Huffington Post that reclassifying marijuana would only serve as a victory to marijuana advocates as it would be distracting and meaningless.

In a law review article submitted in 2013, Sabet argued that for legitimate marijuana research to proceed, it is not a must for marijuana to be rescheduled because the Schedule 1 status of weed does not prevent it from being tested and studied for medical purposes. However, Sabet did not acknowledge the fact that the research programs can be delayed by restrictions laid out on Schedule 1 substances.

Bertha Madras commended the DEA (Drug Enforcement Administration) for rejecting the petition for rescheduling pot. She further said that it would be unethical to move marijuana to Schedule II of controlled substances.

In April, NIDA Director Nora Volkow said that it becomes difficult to research once drugs are classified as Schedule I, which is usually done to protect the public.

This news is likely to be welcomed by the marijuana industry, including Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) and Marijuana Company of America Inc. (OTCQB: MCOA), since the growing consensus that marijuana’s current scheduling is a barrier to research will pile pressure on the federal authorities to revise this classification eventually.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – New Jersey Lawmakers Now Say Voters Will Have Final Say on Marijuana Legalization

In New Jersey, lawmakers are abandoning plans of legalizing marijuana through the legislature and are now looking to enter the proposal on the 2020 ballot for the voters to decide.

On Monday, President of the Senate, Steve Sweeny and the Senate Judiciary Committee Chairman Scutari (D) in a press release said that their efforts to gather more support for the measure did not bear any fruit which is why they have filed a motion to allow New Jersey residents to vote on the matter in a referendum.

In their press release, the leaders said that they are seeking for approval to enter the measure of legalizing adult-use cannabis on the 2020 ballot. The legislation seeking for a public referendum was introduced in the legislature on Monday. The proposal will lead to the establishment of a system that permits people to buy and use cannabis recreationally and responsibly.

They further said that the measure would make it possible for the state to control and ensure that retail outlets are selling safe products. It would also limit marijuana sales to adults only. The state of New Jersey would also be in a position to impose sales tax on marijuana sales.

According to media reports, the plan is for the referendum proposal to be approved by the legislature and set the ballot measure for voters in the 2020 general election. The two leaders are positive that the Senate, Assembly, and voters will approve the proposal.

In a tweet, Governor Phil Murphy said that he is disappointed that the Senate was unable to approve adult-use marijuana. He further noted that the failure would lead to the weekly arrest of about 600 people, the majority of whom will comprise members of the black community. He also said that he is hopeful that the New Jersey residents will approve the ballot measure.

The negotiations for legalizing recreational marijuana went on for months, after which Sweeney noted that legalization would have to be done through the ballot.

The resolution calling for the referendum does not offer a detailed description of the outlook of the proposed market for marijuana. The proposal only states that persons above the age of 21 would be allowed to buy and use weed from licensed retail outlets. And, the Cannabis Regulatory Commission of New Jersey would be responsible for regulating the program. The proposal also suggests that a sales tax would be imposed on marijuana sales.

In the ballot, the voters would be asked if they approve the constitutional amendment legalizing a controlled form of recreational cannabis. The draft question would also state that only people who are 21 years and above are allowed to use marijuana and that a state commission would oversee the cannabis program, as well as the market.

In a press release, the Assembly Speaker, Craig Coughlin, said that the legislation for putting the recreational marijuana question to the voter would be voted on by the Senate.

Smart Approaches to Marijuana, a prohibitionist group, celebrated after the legislature announced plans of giving up on the legalization. They said that they would invest in discouraging New Jersey residents from supporting the ballot legalization measure.

Experts are of the view that this failure to legalize marijuana legislatively may have come as a disappointment to the cannabis industry, including entities like Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) and Marijuana Company of America Inc. (OTCQB: MCOA), that had hoped that the people of New Jersey would soon enjoy the many benefits of marijuana, such as employment opportunities.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

HempNewsBreaks – Marijuana Company of America Inc. (MCOA) hempSMART(TM) Brand Receives Los Angeles Business Journal 2019 Fashion & Beauty Awards Nomination

Innovative hemp and cannabis corporation Marijuana Company of America (OTCQB: MCOA) today announced that its hempSMART(TM) brand products have been nominated by the Los Angeles Business Journal for its 2019 Fashion & Beauty Awards. The company’s proprietary hempSMART(TM) brand consists of premium-quality, lab tested, CBD verified products. The Fashion & Beauty Awards will take place at the LA Grand Hotel in Los Angeles, CA at 6:00 PM on December 12, 2019. “We are thrilled to be recognized and nominated by the Los Angeles Business Journal for our hempSMART(TM) brand of products,” Marijuana Company of America CEO Donald Steinberg stated in the news release. “We have always been committed to producing the highest quality products for the personal health and wellness of our customers, and our beauty line has progressed quite rapidly given the surge in demand. Our revenue has increased almost 840% from year-end 2017 to year-end 2018, which we can attribute to our expanding, high-quality product portfolio line and our international expansion into the U.K., Netherlands, and Scotland. The L.A. Business Journal’s Fashion & Beauty forum is another incredible opportunity for us to showcase our products.”

To view the full press release, visit http://cnw.fm/kOHo7

About Marijuana Company of America

Marijuana Company of America is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART(TM)” that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based and cannabis consumer products; (3) the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreational use; VivaBuds(TM) is the newest subsidiary, delivering quality cannabis products across Southern California; (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop in the U.S. and abroad. For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com.

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://cnw.fm/MCOA

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

HempWireNews is part of the InvestorBrandNetwork.

420 with CNW – Clinical Trials of Cannabis as a Treatment for Pancreatic Cancer Expected

The United States Food and Drug Administration has granted a flavonoid of cannabis (Caflanone) the status of the Orphan Drug. It is estimated that within the next few months, the approved Orphan Drug will be used in clinical trials for treating pancreatic cancer. The clinical trials will involve human subjects.

Flavocure is a drug innovation and development company. The company developed the cannabis flavonoid Caflanone (FBL-03G). The U.S. Food and Drug Administration granted Caflanone the Orphan drug status after it was successful in reducing tumor progression in animals with pancreatic cancer through therapy.

The Executive Chairman of Flavocure, Dr. Henry Lowe, said that the company is happy for the designation of Orphan Drug status by the FDA for Caflanone. He further noted that the appointment is a momentous breakthrough for the Flavocure innovation and drug development program.

Dr. Lowe also said that they expect to start a clinical trial involving human subjects with the New Investigational Drug in the next few months. The clinical trials will be addressing pancreatic cancer.

He added that a new standard of care is required for effective and innovative treatment of pancreatic cancer, and as a recognized leader in the field of drug discovery and development, it is their responsibility to bring a new standard of care to the world.

Dr. Ngeh Toyang, the CEO of Flavocure, said that although less than 200,000 people have been diagnosed with pancreatic cancer per year, it is considered as the most common cause of death among cancer patients in the U.S.

Flavocure and the Harvard Medical School conducted pre-clinical studies and published their findings in the Frontiers in Oncology Journal. People from all over the world have been sending feedback and inquiries about the study results, and this has motivated Flavocure to commence the clinical trials for pancreatic cancer.

The drug granted the Orphan Drug status by the FDA, Caflanone, was derived from a prevalent Cannabis Sativa strain found in Jamaica.

Caflanone, which is rich in phytocannabinoids material, was discovered by Professor Lowe, University of Maryland Medical School, and University of the West Indies Medical School.

The Caflanone is now available commercially and can be used in human clinical studies. The Harvard Medical School developed a nano-drone delivery technology for Caflanone, which was approved by the FDA.

Harvard Medical School conducted pre-clinical studies using Caflanone and the drug portrayed great results in animal models with pancreatic cancer, which were difficult to treat. The medical and research community are optimistic about the potential of the drug. It has also aroused the interest of the patients.

President Ronald Reagan approved the Orphan Drug Act in 1983 to encourage companies to innovate and develop drugs that are geared towards helping patients suffering from rare diseases.

Companies which qualify for Orphan Drug designation receive benefit across all stages of drug development such as a speedy approval process, seven years of market exclusivity, and tax credits on U.S. clinical trials. They are also eligible for Orphan Drug grants, and a waiver of some administrative fees.

It is believed that the entire cannabis industry, including players like Marijuana Company of America Inc. (OTCQB: MCOA) and Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) could be waiting with crossed fingers for the outcome of this planned clinical trial that will expand the confirmed therapeutic benefits of marijuana for cancer patients.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – Senate Approves Bill Banning Feds from Interfering in Medical Marijuana State Programs

On Thursday, the Senate passed the spending legislation which has a provision that ensures that medical marijuana states are protected from federal interference. However, the question on everyone’s mind is if the bill will be signed into law once it gets to the president’s office.

The spending legislation is also referred to as minibus appropriation as it covers funding for Agriculture, commerce, Environment, Food, and Drug Administration, Housing, Interior, Justice, Military Construction, Rural Development, Science, Veteran Affairs, Transportation and Urban Development for the 2020 financial year.

The vote on the bill was overwhelming, with 84 in favor vs. 9 votes against. The legislation also had language related to new hemp and CBD.

The legislation prohibits the Department of Justice from using its resources to persecute persons whose actions comply with state marijuana regulations.

In June, the House approved the Justice Department Appropriation bill which would extend protection to all Cannabis programs including  recreational use and sale in the legalized states in the U.S. Marijuana advocates are hopeful that the Senators will approve the legislation; however, in an interview with some media outlets, some Senators said that it is unlikely for the added policies to be adopted because of the bicameral agreement made by the Congressional leaders which stipulated that no new policy riders are to be added during the appropriation process unless agreed on a bipartisan basis.

If the bicameral conference committee negotiators agree to use the House language in the final legislation, the Senate will send the amended bill to the president’s desk for 2020. If, by 21st November, the spending bill is not signed into law, the government will cease operations. Therefore, to avoid such an incident, the larger chambers may opt to approve the bill previously passed by the Senate.

The political director of NORML, Justin Strekal, said he hopes the House will insist on the inclusion of the provision restricting the feds from interfering with marijuana programs in the legalized states in the minibus spending legislation.

Last week, a separate amendment was added to the minibus appropriation bill by Senator Bob Menedez, calling on the Attorney General to review the criminal justice effects of marijuana legalization. However, the Senate did not consider nor discuss the measure.

Apart from the marijuana protection language, the Senate Appropriations Committee also advanced other policies through the spending process. They approved legislation with additional policies that barred Washington from using the local resources, such as tax revenue, to develop a legal marijuana market. It also approved a provision granting funds to the Department of Agriculture to sanction rules for legal hemp program.

In the House version of the appropriations bill, lawmakers also approved a provision for issuing protection to the banks doing business with the marijuana industry, as well as the removal of the measure barring D.C. from implementing a marijuana market.

The majority of the Senate is Republican, and they are sticking with the bicameral agreement; this may lead to the formation of standalone cannabis legislation, such as the SAFE Banking Act, which would allow banks to work with weed businesses without interference from the Department of Justice.

Analysts are of the view that the entire cannabis industry, including Marijuana Company of America Inc. (OTCQB: MCOA) and VPR Brands LP (OTCQB: VPRB), is waiting with bated breath to see how the final vote on the bill goes.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

420 with CNW – University of Maryland Mulls Offering a Master’s in Marijuana

Summer Kriegshauser is a Washington DC denizen studying for her second master’s degree online. Each day before she goes to work, she logs in to a website and goes through her lectures and classwork. She is hopeful that she will be able to change careers with additional qualifications. She is studying for a Masters of Science in Medical Cannabis Science and Therapeutics.

Kriegshauser is one of the 150 students who are the pioneers of the marijuana masters graduate program at the University of Maryland, Baltimore, in the U.S.

This is a standalone program. However, some universities are providing students with one-off classes on marijuana, and two others have created an undergraduate degree in medicinal plant chemistry, but none has gone as far as Maryland by offering a master’s degree in cannabis.

The program is carried out over a period of two years, and the highest percentage of the courses are online-based. The program comes at a time when the number of states legalizing marijuana for both medical and recreational use is on the rise.  This is creating ever-expanding opportunities for people looking to grow in the cannabis industry, and given the dynamism of the marijuana industry and laws related to weed, the possibilities are bound to keep expanding.

Expertise in marijuana is gained through experience as the industry continues to grow. Those looking to make a career in the marijuana industry are taking a risky gamble because the likelihood of finding a job can be tasking in such fluid circumstances.

Kriegshauser says that she loves everything marijuana, but quitting her job to work at a marijuana dispensary to learn about marijuana was out of the question. She wanted to learn the properties of cannabis, all the compounds such as CBD, and how they interact with the body. She also wanted to learn about dosing and medical marijuana qualifying ailments.

According to the program director Dr. Leah Sera, the university officials at the school of pharmacy noticed that most of their graduates were entering a professional world where marijuana was viewed as an alternative medicine used for treating several illnesses.

Studies show that there is an educational gap when it comes to medical marijuana. Health professionals are requesting that more education on marijuana be availed since patients turn to them when they have a question related to cannabis and therapeutic uses, said Dr. Sera.

Several cannabis programs are being launched in different states across the U.S, and it would be irresponsible if the pharmacy professionals do not act on it.

The idea for the program was first conceived by the school’s dean, Natalie D. Eddington. She received the go-ahead from the Board of Regents and the state’s higher education authorities in May and June, respectively. The Attorney-General gave his go-ahead after he was assured that the students would not be handling marijuana in the school compound.

The university intended for the inaugural class to consist of 50 students, but they were forced to increase the number to 150 after an overwhelming number of 506 individuals applied. The class has students from different states and countries such as Hong Kong and Australia. The required number of courses is four and some electives.

Kriegshauser said that although there is much uncertainty when it comes to getting a job, she is confident that her master’s degree will enhance her professional career.

Industry watchers and the entire cannabis industry, including players like MustGrow Biologics Corp. (CSE: MGRO) and Marijuana Company of America Inc. (OTCQB: MCOA) are glad that higher education institutions are taking the initiative to bridge the knowledge and skills gap existing in the marijuana industry.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com